Filtered By:
Specialty: Cardiology
Condition: Cardiomyopathy

This page shows you your search results in order of date. This is page number 6.

Order by Relevance | Date

Total 533 results found since Jan 2013.

Sex Differences in Characteristics, Outcomes and Treatment Response with Dapagliflozin across the Range of Ejection Fraction in Patients with Heart Failure: Insights from DAPA-HF and DELIVER
CONCLUSIONS: In DAPA-HF and DELIVER, the response to dapagliflozin was similar between men and women. Sex did not modify the treatment effect of dapagliflozin across the range of ejection fraction.PMID:36342789 | DOI:10.1161/CIRCULATIONAHA.122.062832
Source: Circulation - November 7, 2022 Category: Cardiology Authors: Xiaowen Wang Muthiah Vaduganathan Brian L Claggett Sheila M Hegde Maria Pabon Ian J Kulac Orly Vardeny Eileen O'Meara Shelley Zieroth Tzvetana Katova Martina M McGrath Anne-Catherine Pouleur Pardeep S Jhund Akshay S Desai Silvio E Inzucchi Mikhail N Kosib Source Type: research

Proteomics profiling reveals a distinct high-risk molecular subtype of hypertrophic cardiomyopathy
Conclusions Our prospective plasma proteomics study not only exhibited the presence of HCM molecular subtypes but also identified pathobiological mechanisms associated with a distinct high-risk subtype of HCM.
Source: Heart - October 28, 2022 Category: Cardiology Authors: Liang, L. W., Raita, Y., Hasegawa, K., Fifer, M. A., Maurer, M. S., Reilly, M. P., Shimada, Y. J. Tags: Heart failure and cardiomyopathies Source Type: research

New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy
Cardiovasc Hematol Agents Med Chem. 2022 Oct 19. doi: 10.2174/1871525721666221019095218. Online ahead of print.ABSTRACTObstructive hypertrophic cardiomyopathy results from asymmetric septal hypertrophy which eventually obstructs the outflow of the left ventricle. Obstructive hypertrophic cardiomyopathy is linked to mutations in genes that encode for sarcomere proteins including actin, &#946:myosin heavy chain, titin, and troponin. The mutations lead to structural abnormalities in myocytes and myofibrils causing conduction irregularities and abnormal force generation. Obstructive hypertrophic cardiomyopathy is a chronic...
Source: Cardiovascular and Hematological Agents in Medicinal Chemistry - October 24, 2022 Category: Cardiology Authors: Ma'Lik Woodland Rami A Al-Horani Source Type: research

Estimating the Prevalence, Clinical Characteristics, and Treatment Patterns of Hypertrophic Cardiomyopathy in Japan: A Nationwide Medical Claims Database Study
CONCLUSIONS: This study provides important information on the current epidemiological and clinical characteristics of HCM in Japan.PMID:36208832 | DOI:10.1016/j.jjcc.2022.09.015
Source: Journal of Cardiology - October 8, 2022 Category: Cardiology Authors: Naoki Terasaka Dionysis Spanopoulos Hidetaka Miyagoshi Toru Kubo Hiroaki Kitaoka Source Type: research

Exercise oxygen pulse kinetics in patients with hypertrophic cardiomyopathy
Conclusion None of the frequently used CPET parameters, either as absolute values or dynamic relationships, were associated with LVOTO. Differently, an abnormal temporal behaviour of O2-pulse during exercise, which is strongly related to inadequate SV increase, correlates with reduced functional capacity (peak and anaerobic threshold VO2 and workload) and increased VE/VCO2 slope, identifying more advanced disease irrespectively of LVOTO.
Source: Heart - September 26, 2022 Category: Cardiology Authors: Mapelli, M., Romani, S., Magri, D., Merlo, M., Cittar, M., Mase, M., Muratori, M., Gallo, G., Sclafani, M., Carriere, C., Zaffalon, D., Salvioni, E., Mattavelli, I., Vignati, C., De Martino, F., Rovai, S., Autore, C., Sinagra, G., Agostoni, P. Tags: Heart failure and cardiomyopathies Source Type: research